Milestone Pharmaceuticals announces U.S. availability of cardamyst
Milestone Pharmaceuticals (MIST) announced that cardamyst nasal spray, its first commercial product, is now available through U.S. retail pharmacies. Cardamyst is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. Implementation of a rapid commercialization plan is underway with a national sales force to be deployed in mid-February 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
Disclaimer & DisclosureReport an Issue
- Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing
- Milestone Pharmaceuticals: Undervalued CARDAMYST Opportunity with EU Upside and Strong Risk‑Reward Supporting Buy Rating
- Milestone’s PSVT nasal spray MAA accepted by EMA
- Milestone announces acceptance of MAA by EMA for etripamil nasal spray
- Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.